Valneva SE

Valneva SE is a specialty vaccine company. The firm focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. It takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. It operates through the following segments: Commercialized products, COVID, Vaccine candidates and Technologies and services. The Commercialized products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment engages in the development, manufacturing and distribution related to COVID-19 vaccine candidate, VLA2001. The Vaccine candidates segment engages in proprietary research and development programs aiming to generate new approvable products in order to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies, excluding COVID-19 vaccine candidate, VLA2001. The Technologies and services segment provides services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

Saint - Herblain ( France), August 14 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has revised the Prescription Drug User Fee Act (PDUFA) action date for the Biologics License Application (BLA) for VLA1553, Valneva's chikungunya virus vaccine candidate, from the previously communicated end of August to the end of November.

Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate

Positive Phase 3 data from Bavarian Nordic's chikungunya virus (CHIKV) vaccine candidate, PXVX0317, reinforces bullish view on Valneva's VLA1553 due to its superior clinical profile. Valneva's VLA1553 demonstrated impressive seroresponse rates and durability, with future data releases from Bavarian Nordic's additional Phase 3 trial expected to provide a comprehensive comparison between the two vaccines. Valneva has submitted a regulatory application to Health Canada for VLA1553 approval and received Fast Track.

Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race

Saint - Herblain ( France), June 2 2 , 202 3 – Valneva S E (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its Supervisory Board has recommended a change of governance model.

Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors

Saint - Herblain ( France), June 2 1 , 202 3 – Valneva S E (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting (AGM) held today in Lyon, France.

Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer's Former Vaccine R&D Head to its Supervisory Board

Valneva SE Sponsored ADR (VALN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?

Saint- Herb lain (France ) , June 13 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that the Company's pivotal Phase 3 data for its single-shot chikungunya vaccine candidate, VLA1553, have been published in The Lancet , the world's leading peer-reviewed medical journal.

Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet

Saint-Herb lain (France ) , May 3 1 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the availability of documentation for its Combined General Meeting to be held on June 21, 2023 at 2 p.m. CEST, at the hotel InterContinental Lyon – Hotel Dieu, 20 Quai Jules Courmont, 69002 Lyon (France).

Valneva Announces the Availability of Documentation for its Shareholder Meeting

The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.

Valneva (VALN) Stock Down 53% in the Past Year: Here's Why

Saint- Herb lain (France ) , May 30 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the filing of a regulatory application with Health Canada for marketing approval of the Company's single-shot chikungunya vaccine candidate, VLA1553, in persons aged 18 years and above. If accepted, Health Canada will provide additional information on the potential approval timeline.

Valneva Files for Chikungunya Vaccine Authorization with Health Canada

Valneva SE (NASDAQ:VALN ) Q1 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants Joshua Drumm - VP, IR Thomas Lingelbach - Chairman, President & CEO Peter Buhler - CFO Conference Call Participants Kevin Strang - Jefferies Edward White - H.C. Wainwright & Co Boran Wang - Guggenheim Securities Simon Scholes - First Berlin Rajan Sharma - Goldman Sachs Group Samir Devani - Rx Securities Limited Max Herrmann - Stifel, Nicolaus & Company Operator Good day and thank you for standing by.

Valneva SE (VALN) Q1 2023 Earnings Call Transcript

Product sales increased 98.6% to €3 2 . 1 million in the first quarter of 202 3 compared to € 16 . 2 million in the first quarter of 2022

Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Saint - Herblain ( France), March 31 , 20 2 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 30 2023, of its 2022 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.23-0199 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).

Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F

Saint Herblain (France), March 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will present on its single-shot chikungunya vaccine candidate, VLA1553, and host a roundtable on Zika vaccines next week at the 23rd World Vaccine Congress in Washington, D.C.

Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.

Valneva's pipeline and high-stakes clinical catalysts warrant a buy rating, despite the setback in its Lyme disease Phase 3 trial. The CHIKV vaccine candidate is on track for PDUFA in August 2023, and the company plans to launch one or two programs in clinical trials by the close of 2023.

Valneva Q4: Resilient Pipeline And Partnership With Pfizer, Reinforcing A Promising Future

Valneva SE (NASDAQ:VALN ) Q4 2022 Earnings Conference Call March 23, 2023 10:00 AM ET Company Participants Joshua Drumm - Vice President of Investor Relations Thomas Lingelbach - Chief Executive Officer Peter Buhler - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Evan Wang - Guggenheim Securities Max Herrmann - Stifel Nicolaus Rajan Sharma - Goldman Sachs Samir Devani - Rx Securities Operator 0Good day, and thank you for standing by. Welcome to the Valneva Full-Year 2022 Financial Results Conference Call.

Valneva SE (VALN) Q4 2022 Earnings Call Transcript

Total revenue s of €3 6 1 . 3 million in 202 2 compared to €348 . 1 million in 2021

Valneva Reports Full Year 2022 Results and Provides Corporate Updates

Dynavax Technologies

Saint - Herblain ( France), March 2 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001. As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership1. It is, however, completing remaining clinical studies and submissions as agreed with regulators.

Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001

Saint- Herb lain (France) , March 1 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Cowen 43rd Annual Healthcare Conference, to take place in-person March 6 - 8, 2023 in Boston, Massachusetts.

Valneva to Present at the Cowen 43rd Annual Healthcare Conference

Valneva SE is a French biotechnology company specializing in developing and commercializing vaccines. We expect approval of two attractive vaccine candidates targeting Chikungunya and Lyme disease by 2024-2025.

Valneva SE: Underfollowed French Biotech, 2 Interesting Vaccine Approvals Expected In 2023

Saint - Herblain ( France), February 20 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has completed a filing review of its Biologics License Application for Valneva's single-shot chikungunya vaccine candidate VLA1553 and has determined that the application is sufficiently complete to permit a substantive review. The review classification is Priority.

FDA Accepts Valneva's Chikungunya Vaccine License Application for Priority Review

Valneva stock plummeted Friday after Pfizer said it will drop roughly half of the participants enrolled in their Lyme disease vaccine study. The post Valneva Shares Topple As It Hits Ethics Roadblock With Pfizer In Lyme Disease Test appeared first on Investor's Business Daily.

Valneva Shares Topple As It Hits Ethics Roadblock With Pfizer In Lyme Disease Test

Pfizer

New York & Saint- Herblain (France), February 17, 2023 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announce that Pfizer, as the study sponsor, has decided to discontinue a significant percentage of participants in the U.S. who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study. The study is investigating the efficacy, safety and immunogenicity of an investigational Lyme disease vaccine candidate, VLA15. These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator. The discontinuation of these participants was not due to any safety concerns with the investigational vaccine and was not prompted by a participant-reported adverse event.

Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Total revenue s of €3 6 1 . 3 million in 202 2 were ahead of previously communicated guidance of €340 million to €360 million 1 (compared to €348 . 1 million in 2021)

Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance

Saint - Herblain ( France), February 14 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it completed enrollment and vaccination for a Phase 3 trial in adolescents, VLA1553-321, of its single-shot chikungunya vaccine candidate, VLA1553. First results of the trial are expected mid-2023.

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.

News for Valneva SE Stock (VALN)